A Cure for a Childhood Cancer—but Will It Last?
The first time a child gets acute lymphoblastic leukemia it’s worrying, as any cancer would be, but generally curable. If it comes back, a bone marrow transplant could still wipe it out. If it comes back again, it is often a death sentence.
Or at least it was, until an experimental treatment that genetically enhances a patient’s immune system, known as CAR-T, came along. Only tested in humans in the last few years, the results have been astonishing, knocking out almost overnight a cancer that defied all other treatments. Early tests showed that 90 percent of patients went into remission.
There are, unfortunately, two major problems with CAR-T therapy. First, it is dangerous—deaths are not uncommon in clinical trials involving CAR-T. But for many patients the risk of a fatal reaction to the treatment is an acceptable one, given the potential benefit.
The second principal concern is that the cancer will come back. As a heartrending story in the Washington Post describes, by the time children enter into a CAR-T trial they (as well as the families that support them) have already been through hell. In the case of eight-year old Ava Christianson, the focus of the Post’s piece, the cancer survived even a round of CAR-T treatment, in which Ava’s immune cells were harvested from her, genetically modified, and given back to her. She was in for another, newer generation of the treatment, and it appeared to be working.
“We just need this to work and stay working for her,” her mom, Bethany Christianson, told the Post as she held back tears.
That’s the thing about CAR-T. Powerful as it is, it is such a new therapy that no one knows whether the effects are permanent—and if they aren’t, how long they last. Last year, we followed the story of one patient, Milton Wright III, who at 18 months had been one of the treatment’s longest survivors.
The phrase “a cure for cancer” has been around so long, it’s become cliché—a term invoked figuratively to describe a great achievement, or a panacea. As we approach such a cure, however, the reality is turning out to be far more fragile.
(Read more: The Washington Post, “10 Breakthrough Technologies 2016: Immune Engineering,” “Biotech’s Coming Cancer Cure”)
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.